Genprex granted patent in Singapore for Reqorsa gene therapy

Genprex has been granted a patent by the Singapore Patent Office that covers the use of the company’s lead drug candidate, Reqorsa Gene Therapy, in combination with anti-PD-1 antibodies through 2037. This patent expands on the previously granted patents in the U.S., Japan, Mexico, Russia, Australia, Chile, China and Korea to cover the use of REQORSA in combination with an immune checkpoint inhibitor, i.e., PD-1 antibodies. The granted Korean patent also claims the use of REQORSA in combination with PD-L1 antibodies. Genprex will be pursuing additional patent applications with claims to combinations of REQORSA and PD-L1 antibodies in the US, Brazil, Canada, China, Europe and Israel. Should these applications grant, they would be applicable to Genprex’s Acclaim-3 clinical trial. The Acclaim-3 study is a Phase 1/2 clinical trial that uses a combination of REQORSA and Genentech’s Tecentriq as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC) who developed tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. The Acclaim-3 clinical trial has received FDA Fast Track Designation for this patient population, and Acclaim-3 has received FDA Orphan Drug Designation.